Ticker >

ANG Lifesciences share price

ANG Lifesciences India Ltd.

BSE: 540694 SECTOR: Pharmaceuticals & Drugs  18k   117   3

73.00
+1.73 (2.43%)
BSE: 04 Oct 11:43 AM

Price Summary

Today's High

₹ 73.88

Today's Low

₹ 71.25

52 Week High

₹ 159.4

52 Week Low

₹ 52.1

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

95.33 Cr.

Enterprise Value

149.73 Cr.

No. of Shares

1.31 Cr.

P/E

0

P/B

1.09

Face Value

₹ 10

Div. Yield

1.36 %

Book Value (TTM)

₹  66.73

CASH

6.59 Cr.

DEBT

60.99 Cr.

Promoter Holding

70.6 %

EPS (TTM)

₹  -1.84

Sales Growth

126%

ROE

63.62 %

ROCE

53.78%

Profit Growth

447.79 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year126%
3 Year42.03%
5 Year38.81%

Profit Growth

1 Year447.79%
3 Year91.57%
5 Year69.68%

ROE%

1 Year63.62%
3 Year33.99%
5 Year29.61%

ROCE %

1 Year53.78%
3 Year32.02%
5 Year28.39%

Debt/Equity

0.7306

Price to Cash Flow

3.48

Interest Cover Ratio

7.38389817254364

CFO/PAT (5 Yr. Avg.)

0.470510435711943

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2023 70.6 44.88
Mar 2023 70.6 44.88
Dec 2022 71.15 44.88
Sep 2022 71.15 44.88
Jun 2022 71.15 44.88
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 91.5670140227155% for the Past 3 years.
  • The company has shown a good revenue growth of 42.0277257545102% for the Past 3 years.
  • Company has been maintaining healthy ROE of 33.9921363965385% over the past 3 years.
  • Company has been maintaining healthy ROCE of 32.0228333312031% over the past 3 years.
  • The company has an efficient Cash Conversion Cycle of 19.4530139501271 days.

 Limitations

  • Promoter pledging is high as 44.88%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
Net Sales 71.56 58.4 45.17 31.88 50.61
Total Expenditure 60.28 49.15 43.03 43.48 44.94
Operating Profit 11.28 9.24 2.14 -11.59 5.67
Other Income 0.12 0.2 0.32 9.2 0.34
Interest 3.18 3.2 2.84 1.11 1.94
Depreciation 1.88 1.9 1.92 2.82 1.94
Exceptional Items 0 0 0 0 0
Profit Before Tax 6.35 4.34 -2.3 -6.33 2.14
Tax 3.01 1.72 -0.7 -1.3 0.54
Profit After Tax 3.34 2.62 -1.6 -5.03 1.6
Adjusted EPS (Rs) 2.58 2.02 -1.22 -3.85 1.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 76.04 121.7 126.83 154.28 348.67
Total Expenditure 68.54 109.87 114.15 138.94 283.12
Operating Profit 7.5 11.83 12.68 15.33 65.54
Other Income 0.69 0.23 0.42 0.75 0.95
Interest 2.04 2.83 3.46 3.98 8.31
Depreciation 1.19 1.12 1.23 2.24 5.12
Exceptional Items 0 0 0 0 0
Profit Before Tax 4.95 8.11 8.41 9.86 53.06
Tax 1.23 2.46 2.31 2.61 13.35
Net Profit 3.72 5.65 6.1 7.25 39.71
Adjusted EPS (Rs.) 2.87 4.36 4.7 5.59 30.65

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 5.18 5.18 5.18 5.18 10.37
Total Reserves 17.99 23.58 29.37 36.17 73.11
Borrowings 7.68 6.28 5.25 5.93 12.01
Other N/C liabilities 1.87 3.45 3.37 2.69 19.28
Current liabilities 35.45 42.4 50.9 91.86 153.92
Total Liabilities 68.17 80.9 94.08 141.83 268.68
Assets
Net Block 21.04 20.76 21.17 21.89 82.32
Capital WIP 0 0 0 0.4 0
Intangible WIP 0 0 0 0 0
Investments 0.02 0.02 0.02 0.02 3.52
Loans & Advances 0.23 0.16 0.21 3.88 0.39
Other N/C Assets 0 0 0 3.75 0.88
Current Assets 46.87 59.96 72.67 111.89 181.57
Total Assets 68.17 80.9 94.08 141.83 268.68
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 3.72 8.11 8.41 9.86 53.06
Adjustment 4 3.4 4.1 5.87 14.83
Changes in Assets & Liabilities -5.81 -1.68 -5.02 -26.29 -39.92
Tax Paid -1.03 -2.37 -2.65 -0.63 -0.58
Operating Cash Flow 0.88 7.46 4.83 -11.18 27.39
Investing Cash Flow -13.4 -0.77 -1.66 -7.79 -42.5
Financing Cash Flow 13.1 -3.8 -3.95 18.81 15.29
Net Cash Flow 0.57 2.89 -0.77 -0.16 0.17

Corporate Actions

Investors Details

PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
promoters 71.15 71.15 71.15 70.60 70.60
rajesh gupta 70.95 70.95 70.95 70.41 70.41
saruchi gupta 0.19 0.19 0.19 0.19 0.19
PARTICULARS Mar 2019% Sep 2019% Mar 2020% Sep 2020% Mar 2021%
investors 28.99 28.99 28.99 28.99 28.99
arun bhanot - - - 1.33 1.27
ways vinimay private limi... 8.30 8.30 7.84 6.91 5.53
display commercial privat... - - - 1.48 -
globe capital market limi... 1.70 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ3FY22 23 Feb 2022
  • PresentationQ2FY22 29 Oct 2021
  • PresentationQ1FY22 10 Sep 2021

ANG Lifesciences Stock Price Analysis and Quick Research Report. Is ANG Lifesciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into ANG Lifesciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 27.3877 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. ANG Lifesciences has a Debt to Equity ratio of 0.7306 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In ANG Lifesciences , the EPS growth was 447.794301648018 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, ANG Lifesciences has OPM of 18.7984663982558 % which is a good sign for profitability.
     
  • ROE: ANG Lifesciences have a healthy ROE of 63.6235615288367 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Last Updated on:
Brief about ANG Lifesciences
X